U.S. Markets close in 5 hrs 31 mins

VYNE Therapeutics Inc. (VYNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6846-0.0354 (-2.06%)
As of 10:29AM EST. Market open.

VYNE Therapeutics Inc.

520 U.S. Highway 22
Suite 305
Bridgewater, NJ 08807
United States
800 775 7936
http://www.vynetherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Mr. David T. DomzalskiCEO, Pres & Director891kN/A1967
Ms. Mutya HarschGen. Counsel, Chief Legal Officer & Company Sec.556kN/A1975
Dr. Darrell S. Rigel M.S., M.D., MSConsultant40.2kN/A1950
Mr. Andrew SaikCFO & TreasurerN/AN/A1969
Dr. Iain A. StuartChief Scientific OfficerN/AN/A1973
Mr. Raymond G. SteitzSr. VP of Global HRN/AN/A1959
Dr. Russell ElliottSr. VP of Pharmaceutical Devel.N/AN/A1966
Mr. Matthew WileyChief Commercial OfficerN/AN/A1972
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

VYNE Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.